Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Hui MD, MSc

David Hui MD, MSc

Professor of Medicine; Director of Research, Supportive/Palliative Care; Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Dr. David Hui is a tenured professor and Director of Research at the Department of Palliative Care, Rehabilitation and Integrative Medicine, with a joint appointment to the Department of General Oncology at the University of Texas MD Anderson Cancer Center, Houston, USA. His research interests include integration of supportive/palliative care and oncology, symptom management clinical trials, prognostication, and research methodology. He is the principal investigator of multiple randomized trials on dyspnea and delirium funded by the National Cancer Institute. His research is also supported by the National Institute of Nursing Research, the American Cancer Society and other agencies. He has authored and/or co-authored over 300 scientific papers, with his work appearing at various peer-review journals such as JAMA, JAMA Oncol, J Clin Oncol, CA: A Cancer Journal for Clinicians, Lancet Oncol and Ann Oncol. Dr. Hui currently serves as a standing member of a study section at the National Institutes of Health. He is also a senior associate editor of the Journal of Pain and Symptom Management. In addition to academic pursuits, he remains active clinically in both palliative care and medical oncology.

Disclosures

No disclosure reported.